IDEXX SDMA Now Integrated into the Most Common Catalyst Chemistry Profiles

Key Terms

sdma medical

Symmetric dimethylarginine (SDMA) is a small molecule released into the blood when cells break down, and levels rise when the kidneys stop clearing waste efficiently. Measured by blood tests, it often signals declining kidney function earlier than traditional measures, so it acts like an early smoke detector for renal problems. For investors, SDMA matters because it underpins diagnostic tests, treatments and monitoring tools that can drive product adoption, clinical utility and recurring revenue in healthcare and veterinary markets.

renal biomarker medical

A renal biomarker is a measurable molecule or test result that indicates how well the kidneys are working or whether they are injured, similar to a car’s oil gauge showing engine health. Investors watch these markers because they help judge a drug’s safety and effectiveness in clinical trials, forecast treatment costs and patient outcomes, and affect regulatory approval and a company’s financial prospects.

chronic kidney disease medical

Chronic kidney disease is a long-term, progressive loss of kidney function that reduces the organs’ ability to filter waste, control fluid levels and balance body salts. For investors, CKD matters because it creates sustained demand for tests, drugs, dialysis machines and transplants; advances in treatment or regulatory decisions can meaningfully change revenue prospects for companies—like a car that needs ongoing repairs, it creates predictable, long-term market needs.

creatinine medical

A waste molecule produced by muscle activity and cleared from the blood by the kidneys; doctors measure blood creatinine to judge how well kidneys are working. For investors, changes in creatinine levels matter because they can affect drug dosing, safety signals, trial eligibility and regulatory decisions—think of it like a car’s oil light that signals whether the engine (kidneys) can handle a treatment or condition, which in turn can influence clinical outcomes and company valuations.

biomarker medical

A biomarker is a measurable indicator found in the body, such as in blood or tissues, that provides information about health, disease, or how the body responds to treatment. For investors, biomarkers can signal the potential success or risk of medical products or therapies, influencing the value of related companies and industry trends. They act like signals or clues that help assess the progress of medical advancements and their market impact.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Built-in SDMA delivers earlier insights with seamless workflow

WESTBROOK, Maine--(BUSINESS WIRE)-- IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, today announced that SDMA, a renal biomarker, will be built into Catalyst™ CLIPs, making complete kidney function evaluation part of the most common point-of-care chemistry profiles. Available beginning in June to customers in the United States and Canada, the integration expands access to advanced kidney assessment at scale, enabling veterinarians to identify kidney function loss earlier and act sooner, without disrupting familiar workflows.

Catalyst SDMA Testing

Supported by peer-reviewed studies using the IDEXX SDMA™ Test, SDMA is recognized by the International Renal Interest Society (IRIS) as a key biomarker for evaluating kidney function in pets.¹ Since introducing the IDEXX SDMA™ Test in 2015, IDEXX has performed approximately 119 million SDMA patient tests globally primarily through its reference laboratories and increasingly on the Catalyst platform,² underscoring the test’s clinical importance and broad adoption in kidney health evaluation. Results are seamlessly integrated into VetConnect™ PLUS, alongside other diagnostic data.

“SDMA is a clear example of how IDEXX innovates by developing clinically relevant diagnostics and then scaling their impact through platforms veterinarians already use every day,” said Mike Erickson, President and CEO of IDEXX. “Earlier insight enables earlier action, improving outcomes for pets, strengthening care experiences, and supporting durable, long-term growth for veterinary practices and IDEXX.”

Chronic kidney disease (CKD) is common in dogs and cats and frequently unrecognized, particularly early in the disease. Clinical evidence continues to show that including SDMA in routine diagnostic testing enables earlier detection of meaningful declines in kidney function that conventional markers alone may miss.^3–6 In addition, a study, published in the Journal of the American Veterinary Medical Association, found that cats with early-stage CKD treated with a renal diet experienced slower disease progression and improved survival.⁷

“Kidney disease is common in both cats and dogs, so early evaluation is important,” said Dr. Christine Kirnos, VMD, The Cat Hospital of Media.* “Making SDMA easier to incorporate into routine in-clinic chemistry testing helps us assess kidney health more consistently and provides meaningful insight during the patient visit.”

For more information, please visit the Catalyst testing web page.

*Dr. Kirnos has received compensation for consulting services she has provided to IDEXX.

References

1. IRIS Guidelines. International Renal Interest Society. Accessed May 1, 2026. www.iris-kidney.com/iris-guidelines-1
2. Data on file at IDEXX Reference Laboratories, Inc. Westbrook, Maine USA: Catalyst SDMA and IDEXX SDMA test results collected July 13, 2015–March 31, 2026.
3. Hall JA, Yerramilli M, Obare E, Yerramilli M, Almes K, Jewell DE. Serum concentrations of symmetric dimethylarginine and creatinine in dogs with naturally occurring chronic kidney disease. J Vet Intern Med. 2016;30(3):794–802. doi:10.1111/jvim.13942
4. Nabity MB, Lees GE, Boggess MM, et al. Symmetric dimethylarginine assay validation, stability, and evaluation as a marker for the early detection of chronic kidney disease in dogs. J Vet Intern Med. 2015;29(4):1036–1044. doi:10.1111/jvim.12835
5. Hall JA, Yerramilli M, Obare E, Yerramilli M, Jewell DE. Comparison of serum concentrations of symmetric dimethylarginine and creatinine as kidney function biomarkers in cats with chronic kidney disease. J Vet Intern Med. 2014;28(6):1676–1683. doi:10.1111/jvim.12445
6. Ettinger SJ, Feldman EC, eds. Textbook of Veterinary Internal Medicine. 6th ed. St. Louis, MO: Elsevier; 2005:1718–1719.
7. Coyne M, Szlosek D, Webeck J, et al. Use of a veterinary therapeutic renal diet in cats with early chronic kidney disease is associated with slower disease progression and improved survival. JAVMA. 2026;264(5):590–598. doi:10.2460/javma.25.10.0665

About IDEXX

IDEXX is a global leader in pet healthcare innovation. Our diagnostic and software products and services create clarity in the complex, constantly evolving world of veterinary medicine. We support longer, fuller lives for pets by delivering insights and solutions that help the veterinary community around the world make confident decisions—to advance medical care, improve efficiency, and build thriving practices. Our innovations also help ensure the safety of milk and water across the world and maintain the health and well-being of people and livestock. IDEXX Laboratories, Inc. is a member of the S&P 500™ Index. Headquartered in Maine, IDEXX employs approximately 11,000 people and offers solutions and products to customers in more than 175 countries and territories. For more information about IDEXX, visit: www.idexx.com.

Note Regarding Forward-Looking Statements

This news release contains or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by the use of words such as “expects,” “may,” “anticipates,” “intends,” “would,” “will,” “plans,” “believes,” “estimates,” “should,” “project,” and similar words and expressions. These forward-looking statements are intended to provide our current expectations or forecasts of future events; are based on current estimates, projections, beliefs, and assumptions; and are not guarantees of future performance. Actual events or results may differ materially from those described in the forward-looking statements. These statements are subject to risks, uncertainties, assumptions, and other important factors. Readers are cautioned not to put undue reliance on such forward-looking statements because actual results may vary materially from those expressed or implied. The reports filed by IDEXX pursuant to United States securities laws contain discussions of some of these risks and uncertainties. IDEXX assumes no obligation to, and expressly disclaims any obligation to, update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise. Readers are advised to review IDEXX’s filings with the United States Securities and Exchange Commission (which are available from the SEC’s EDGAR database at sec.gov and via IDEXX’s website at idexx.com).

View source version on businesswire.com: https://www.businesswire.com/news/home/20260519642899/en/

Media Relations
media@idexx.com

Investor Relations
investorrelations@idexx.com

Source: IDEXX Laboratories, Inc.